Earnings ·
Phathom reports Q3 net revenues of $84.7 million, up 71% year over year
PHATPhathom Pharmaceuticals, Inc.
Phathom Pharmaceuticals reported third-quarter 2026 net revenues of $84.7 million, a 71% increase from the prior-year period and a 14% sequential rise. The company generated positive operating cash flow for the second consecutive quarter and posted a GAAP net loss of $13.9 million, compared to a $30.0 million loss in Q3 2025. Non-GAAP adjusted net income was $3.0 million. VOQUEZNA prescriptions exceeded 2 million total since launch, with approximately 380,000 filled in the quarter. Phathom reaffirmed its full-year 2026 revenue guidance of $310–$325 million and noted the initiation of a Phase 3 trial for as-needed use in NERD. The company operates in the biopharmaceutical industry, commercializing novel treatments for gastrointestinal diseases.